Based upon the preliminary results seen in an animal model, this study is designed to determine if a similar response to the drug AVR118 can be demonstrated in humans. The study population will be divided into two cohorts of patients who will undergo a one-week course of therapy.
The first cohort of patients will have undergone plastic surgery and must present a minimum of two bilateral surgical wounds. AVR118 will be applied to one wound so that the second wound will serve as an untreated control. The objective is to determine if AVR 118 can accelerate the time taken for the wound to close. A secondary objective will determine if AVR 118 can reduce or eliminate scar formation.
The second cohort of patients will have undergone an exfoliative dermatologic procedure for eliminating acne induced scaring known as derm-abrasion. Following the derm-abrasion therapy, AVR 118 will be applied directly to one half of the inflamed facial tissue using the topically applied AVR 118 spray. The other half of the face will serve as an untreated control. The objective is to determine if AVR 118 can effectively reduce inflammation and accelerate the rate of tissue regeneration.
Advanced Viral Research said that, if the study was successful, the drug could be used alone or in combination with other drugs to facilitate wound healing.